{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:41:52Z","timestamp":1792716112616,"version":"4.5.0"},"reference-count":70,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T00:00:00Z","timestamp":1685664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Uterine cancer has the highest incidence and the second-highest mortality rate among gynecologic malignancies in the United States. Although uterine serous carcinoma (USC) represents less than 10% of endometrial carcinomas, it accounts for a disproportionate 50% of tumor relapses and 40% of endometrial cancer deaths. Over the past decade, clinical trials have focused on finding better treatments for this aggressive subtype of endometrial cancer, especially HER2-targeted therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a literature search in PubMed to expand the understanding of HER2 in USC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>HER2 has been established as an important biomarker with prognostic and therapeutic implications in USC. Intratumoral heterogeneity and lateral\/basolateral membranous staining of HER2 as well as high discordance between HER2 immunohistochemistry and in situ hybridization are more common in USC than in breast carcinoma. Therefore, a universal HER2 testing and scoring system more suitable to endometrial cancer is needed and currently under investigation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This review discusses the clinical perspective of HER2 overexpression\/gene amplification in USC, the distinct HER2 staining pattern and the evaluation of HER2 in USC, the resistance mechanisms of HER2-targeted therapy in HER2-positive cancers, and likely areas of future investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqad056","type":"journal-article","created":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T16:19:09Z","timestamp":1684945149000},"page":"341-351","source":"Crossref","is-referenced-by-count":10,"title":["HER2 in uterine serous carcinoma: Current state and clinical perspectives"],"prefix":"10.1093","volume":"160","author":[{"given":"Janira M","family":"Navarro Sanchez","sequence":"first","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Finkelman","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley M","family":"Turner","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Katerji","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharlin","family":"Varghese","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiannan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Southern California , Los Angeles, CA , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Pathology and Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center , Dallas, TX , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G","family":"Hicks","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4208-7680","authenticated-orcid":false,"given":"Huina","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Rochester Medical Center , Rochester, NY , US"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,6,2]]},"reference":[{"key":"2023100314251568100_CIT0001","author":"Surveillance, Epidemiology and End Results Program"},{"issue":"2","key":"2023100314251568100_CIT0002","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1006\/gyno.1997.4617","article-title":"Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women","volume":"65","author":"Matthews","year":"1997","journal-title":"Gynecol Oncol."},{"issue":"5","key":"2023100314251568100_CIT0003","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","article-title":"Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers","volume":"94","author":"Hamilton","year":"2006","journal-title":"Br J Cancer."},{"issue":"1","key":"2023100314251568100_CIT0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/IGC.0000000000000844","article-title":"Survival differences among uterine papillary serous, clear cell and grade 3 endometrioid adenocarcinoma endometrial cancers: a National Cancer Database Analysis","volume":"27","author":"McGunigal","year":"2017","journal-title":"Int J Gynecol Cancer."},{"issue":"8","key":"2023100314251568100_CIT0005","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1136\/ijgc-2020-001379","article-title":"Adjuvant treatment for patients with FIGO stage I uterine serous carcinoma confined to the endometrium","volume":"30","author":"Nasioudis","year":"2020","journal-title":"Int J Gynecol Cancer."},{"issue":"94","key":"2023100314251568100_CIT0006","doi-asserted-by":"crossref","first-page":"36652","DOI":"10.18632\/oncotarget.26413","article-title":"Targeting Her2\/neu in uterine serous carcinoma: a paradigm shift in management","volume":"9","author":"Lopez","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2023100314251568100_CIT0007","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1525-1438.2007.00946.x","article-title":"HER-2\/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization","volume":"18","author":"Odicino","year":"2008","journal-title":"Int J Gynecol Cancer."},{"issue":"5994","key":"2023100314251568100_CIT0008","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/312513a0","article-title":"The neu oncogene: an erb-B-related gene encoding a 85,000-M, tumour antigen","volume":"312","author":"Schechter","year":"1984","journal-title":"Nature."},{"issue":"1","key":"2023100314251568100_CIT0009","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/nrclinonc.2011.177","article-title":"Treatment of HER2-positive breast cancer: current status and future perspectives","volume":"9","author":"Arteaga","year":"2012","journal-title":"Nat Rev Clin Oncol."},{"issue":"45","key":"2023100314251568100_CIT0010","doi-asserted-by":"crossref","first-page":"6469","DOI":"10.1038\/sj.onc.1210477","article-title":"The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis","volume":"26","author":"Moasser","year":"2007","journal-title":"Oncogene."},{"issue":"6","key":"2023100314251568100_CIT0011","first-page":"92","article-title":"HER-2\/neu (erbB-2) and the cell cycle","volume":"27","author":"Busse","year":"2000","journal-title":"Semin Oncol."},{"issue":"12","key":"2023100314251568100_CIT0012","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med."},{"issue":"20","key":"2023100314251568100_CIT0013","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J Clin Oncol."},{"issue":"15","key":"2023100314251568100_CIT0014","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1200\/JCO.2004.11.154","article-title":"Her-2\/neu overexpression and amplification in uterine papillary serous carcinoma","volume":"22","author":"Slomovitz","year":"2004","journal-title":"J Clin Oncol."},{"issue":"5","key":"2023100314251568100_CIT0015","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1111\/j.1349-7006.2012.02240.x","article-title":"Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma","volume":"103","author":"Togami","year":"2012","journal-title":"Cancer Sci."},{"issue":"5","key":"2023100314251568100_CIT0016","first-page":"1271","article-title":"Overexpression of HER-2\/Neu in uterine serous papillary cancer","volume":"8","author":"Santin","year":"2002","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2023100314251568100_CIT0017","doi-asserted-by":"crossref","first-page":"343","DOI":"10.5858\/arpa.2012-0416-RA","article-title":"HER2\/neu in endometrial cancer: a promising therapeutic target with diagnostic challenges","volume":"138","author":"Buza","year":"2014","journal-title":"Arch Pathol Lab Med."},{"issue":"6","key":"2023100314251568100_CIT0018","doi-asserted-by":"crossref","first-page":"687","DOI":"10.5858\/arpa.2020-0207-RA","article-title":"HER2 testing in endometrial serous carcinoma time for standardized pathology practice to meet the clinical demand","volume":"145","author":"Buza","year":"2021","journal-title":"Arch Pathol Lab Med."},{"issue":"1","key":"2023100314251568100_CIT0019","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","article-title":"An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a gynecologic oncology group study","volume":"108","author":"Grushko","year":"2008","journal-title":"Gynecol Oncol."},{"issue":"2","key":"2023100314251568100_CIT0020","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/00004347-199904000-00007","article-title":"HER-2\/neu amplification and overexpression in endometrial carcinoma","volume":"18","author":"Rolitsky","year":"1999","journal-title":"Int J Gynecol Pathol."},{"issue":"15","key":"2023100314251568100_CIT0021","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","article-title":"HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients","volume":"24","author":"Morrison","year":"2006","journal-title":"J Clin Oncol."},{"issue":"7","key":"2023100314251568100_CIT0022","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1002\/cncr.21308","article-title":"Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma","volume":"104","author":"Santin","year":"2005","journal-title":"Cancer."},{"issue":"1","key":"2023100314251568100_CIT0023","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol."},{"issue":"2","key":"2023100314251568100_CIT0024","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1365-2559.2009.03464.x","article-title":"HER-2\/neu receptor gene status in endometrial carcinomas: a tissue microarray study","volume":"56","author":"Xu","year":"2010","journal-title":"Histopathology."},{"issue":"12","key":"2023100314251568100_CIT0025","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","article-title":"Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice","volume":"26","author":"Buza","year":"2013","journal-title":"Mod Pathol."},{"key":"2023100314251568100_CIT0026","first-page":"S0090-8258(22):00592-3","article-title":"HER2 in uterine serous carcinoma: testing platforms and implications for targeted therapy","author":"Klc","year":"2022","journal-title":"Gynecol Oncol."},{"issue":"1","key":"2023100314251568100_CIT0027","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","article-title":"Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study","volume":"159","author":"Erickson","year":"2020","journal-title":"Gynecol Oncol."},{"issue":"3","key":"2023100314251568100_CIT0028","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ajog.2004.10.605","article-title":"Racial differences in the overexpression of epidermal growth factor type II receptor (HER2\/neu): a major prognostic indicator in uterine serous papillary cancer","volume":"192","author":"Santin","year":"2005","journal-title":"Am J Obstet Gynecol."},{"issue":"5","key":"2023100314251568100_CIT0029","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1111\/j.1525-1438.2006.00664.x","article-title":"HER-2\/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications","volume":"16","author":"Villella","year":"2006","journal-title":"Int J Gynecol Cancer."},{"issue":"2","key":"2023100314251568100_CIT0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ijgo.2008.04.008","article-title":"Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2\/neu","volume":"102","author":"Santin","year":"2008","journal-title":"Int J Gynaecol Obstet."},{"issue":"1","key":"2023100314251568100_CIT0031","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ygyno.2010.01.043","article-title":"Letter to the editor referring to the manuscript entitled: \u201cPhase II trial of trastuzumab in women with advanced or recurrent HER-positive endometrial carcinoma: a Gynecologic Oncology Group study\u201d recently reported by Fleming et al., (Gynecol Oncol., 116;15-20;2010)","volume":"118","author":"Santin","year":"2010","journal-title":"Gynecol Oncol"},{"issue":"20","key":"2023100314251568100_CIT0032","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol."},{"issue":"15","key":"2023100314251568100_CIT0033","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","article-title":"Randomized phase II trial of carboplatin\u2013paclitaxel compared with carboplatin\u2013paclitaxel\u2013trastuzumab in advanced (stage III\u2013IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis","volume":"26","author":"Fader","year":"2020","journal-title":"Clin Cancer Res."},{"issue":"1","key":"2023100314251568100_CIT0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3109\/10520295.2011.591830","article-title":"HER2 testing in gastric and esophageal adenocarcinoma: new diagnostic challenges arising from new therapeutic options","volume":"87","author":"Koltz","year":"2012","journal-title":"Biotech Histochem."},{"issue":"1","key":"2023100314251568100_CIT0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/PAP.0b013e3182026d72","article-title":"HER2 testing in gastric cancer","volume":"18","author":"Albarello","year":"2011","journal-title":"Adv Anat Pathol."},{"issue":"12","key":"2023100314251568100_CIT0036","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/gcc.22113","article-title":"Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma","volume":"52","author":"Buza","year":"2013","journal-title":"Genes Chromosomes Cancer."},{"issue":"141","key":"2023100314251568100_CIT0037","first-page":"39","article-title":"Mechanisms of resistance to HER2-targeted therapies in HER2-amplified uterine serous carcinoma, and strategies to overcome it","volume":"26","author":"Menderes","year":"2018","journal-title":"Discov Med."},{"issue":"1","key":"2023100314251568100_CIT0038","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pathol.2022.11.004","article-title":"The role of HER2 as a therapeutic biomarker in gynaecological malignancy: potential for use beyond uterine serous carcinoma","volume":"55","author":"Talia","year":"2023","journal-title":"Pathology."},{"issue":"7","key":"2023100314251568100_CIT0039","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/s41379-020-0461-z","article-title":"Intense basolateral membrane staining indicates HER2 positivity in invasive micropapillary breast carcinoma","volume":"33","author":"Zhou","year":"2020","journal-title":"Mod Pathol."},{"issue":"5","key":"2023100314251568100_CIT0040","first-page":"0","article-title":"Characteristics of HER2 gene amplification by fluorescence in situ hybridization in endometrial serous carcinoma","volume":"146","author":"Buza","year":"2022","journal-title":"Arch Pathol Lab Med."},{"issue":"6","key":"2023100314251568100_CIT0041","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/s41379-021-00746-5","article-title":"Reproducibility of scoring criteria for HER2 immunohistochemistry in endometrial serous carcinoma: a multi-institutional interobserver agreement study","volume":"34","author":"Buza","year":"2021","journal-title":"Mod Pathol."},{"issue":"5","key":"2023100314251568100_CIT0042","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","article-title":"HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma","volume":"45","author":"Banet","year":"2021","journal-title":"Am J Surg Pathol."},{"issue":"1","key":"2023100314251568100_CIT0043","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/GCO.0000000000000599","article-title":"Targeting human epidermal growth factor receptor 2 (HER2) in gynecologic malignancies","volume":"32","author":"Erickson","year":"2020","journal-title":"Curr Opin Obstet Gynecol."},{"issue":"8","key":"2023100314251568100_CIT0044","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1073\/pnas.1222577110","article-title":"Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma","volume":"110","author":"Zhao","year":"2013","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2023100314251568100_CIT0045","article-title":"Current laboratory testing practices for assessment of ERBB2\/HER2 in endometrial serous carcinoma and colorectal carcinoma","author":"Hagemann","year":"2022","journal-title":"Arch Pathol Lab Med."},{"key":"2023100314251568100_CIT0046","article-title":"Evaluating HER2 status using HER2 gene protein assay in endometrial cancer","author":"Shafi"},{"issue":"9","key":"2023100314251568100_CIT0047","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/bjc.2012.132","article-title":"Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2\/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy","volume":"106","author":"Bellone","year":"2012","journal-title":"Br J Cancer."},{"key":"2023100314251568100_CIT0048","doi-asserted-by":"crossref","first-page":"128295","DOI":"10.1155\/2011\/128295","article-title":"erbB2 overexpression in uterine serous cancer: a molecular target for trastuzumab therapy","volume":"2011","author":"Elsahwi","year":"2011","journal-title":"Obstet Gynecol Int"},{"issue":"1","key":"2023100314251568100_CIT0049","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.ygyno.2020.10.018","article-title":"Trastuzumab with carboplatin\/paclitaxel for treatment of advanced stage and recurrent uterine papillary serous carcinoma: a cost-effectiveness analysis","volume":"160","author":"Batman","year":"2021","journal-title":"Gynecol Oncol."},{"issue":"3","key":"2023100314251568100_CIT0050","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1158\/1535-7163.MCT-14-0881-T","article-title":"The preclinical profile of the duocarmycin-based HER2-targeting ADC SYD985 predicts for clinical benefit in low HER2-expressing breast cancers","volume":"14","author":"van der Lee","year":"2015","journal-title":"Mol Cancer Ther."},{"issue":"8","key":"2023100314251568100_CIT0051","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1535-7163.MCT-16-0163","article-title":"SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2\/neu expression","volume":"15","author":"Black","year":"2016","journal-title":"Mol Cancer Ther."},{"issue":"5","key":"2023100314251568100_CIT0052","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1002\/cam4.274","article-title":"T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo","volume":"3","author":"English","year":"2014","journal-title":"Cancer Med"},{"issue":"2","key":"2023100314251568100_CIT0053","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.ygyno.2021.08.014","article-title":"DHES0815A, a novel antibody-drug conjugate targeting HER2\/neu, is highly active against uterine serous carcinomas in vitro and in vivo","volume":"163","author":"Tymon-Rosario","year":"2021","journal-title":"Gynecol Oncol."},{"key":"2023100314251568100_CIT0054","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.gore.2016.12.003","article-title":"Regression of metastatic, radiation\/chemotherapy-resistant uterine serous carcinoma overexpressing HER2\/neu with trastuzumab emtansine (TDM-1)","volume":"19","author":"Santin","year":"2017","journal-title":"Gynecol Oncol Rep"},{"issue":"8","key":"2023100314251568100_CIT0055","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","article-title":"Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study","volume":"20","author":"Banerji","year":"2019","journal-title":"Lancet Oncol."},{"issue":"9","key":"2023100314251568100_CIT0056","first-page":"2531","article-title":"Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence","volume":"5","author":"Segovia-Mendoza","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"2","key":"2023100314251568100_CIT0057","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ygyno.2022.05.021","article-title":"Synergistic activity of neratinib in combination with olaparib in uterine serous carcinoma overexpressing HER2\/neu","volume":"166","author":"Yadav","year":"2022","journal-title":"Gynecol Oncol."},{"issue":"7","key":"2023100314251568100_CIT0058","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/bjc.2015.306","article-title":"PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2\/neu overexpressing uterine serous carcinomas","volume":"113","author":"Black","year":"2015","journal-title":"Br J Cancer"},{"issue":"1","key":"2023100314251568100_CIT0059","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1615\/CritRevOncog.v17.i1.20","article-title":"Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications","volume":"17","author":"Rexer","year":"2012","journal-title":"Crit Rev Oncog."},{"issue":"16","key":"2023100314251568100_CIT0060","doi-asserted-by":"crossref","first-page":"4909","DOI":"10.1158\/1078-0432.CCR-07-0701","article-title":"Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network","volume":"13","author":"Ritter","year":"2007","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2023100314251568100_CIT0061","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.semcdb.2010.08.007","article-title":"The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics","volume":"21","author":"Amin","year":"2010","journal-title":"Semin Cell Dev Biol."},{"issue":"3","key":"2023100314251568100_CIT0062","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/0008-5472.CAN-05-1182","article-title":"Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells","volume":"66","author":"Konecny","year":"2006","journal-title":"Cancer Res."},{"issue":"8","key":"2023100314251568100_CIT0063","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/jnci\/djk134","article-title":"Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer","volume":"99","author":"Scaltriti","year":"2007","journal-title":"J Natl Cancer Inst."},{"issue":"3","key":"2023100314251568100_CIT0064","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/bjc.2016.198","article-title":"Dual CCNE1\/PIK3CA targeting is synergistic in CCNE1-amplified\/PIK3CA-mutated uterine serous carcinomas in vitro and in vivo","volume":"115","author":"Cocco","year":"2016","journal-title":"Br J Cancer."},{"issue":"11","key":"2023100314251568100_CIT0065","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1158\/1535-7163.MCT-15-0383","article-title":"Dual HER2\/PIK3CA targeting overcomes single-agent acquired resistance in HER2-amplified uterine serous carcinoma cell lines in vitro and in vivo","volume":"14","author":"Lopez","year":"2015","journal-title":"Mol Cancer Ther."},{"issue":"11","key":"2023100314251568100_CIT0066","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2018-0902-SA","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice guideline focused update","volume":"142","author":"Wolff","year":"2018","journal-title":"Arch Pathol Lab Med."},{"issue":"5","key":"2023100314251568100_CIT0067","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/ajcp\/aqy166","article-title":"Impact of specimen type and specimen number on HER2 status in gastroesophageal junction and gastric adenocarcinoma","volume":"151","author":"Huber","year":"2019","journal-title":"Am J Clin Pathol."},{"issue":"3","key":"2023100314251568100_CIT0068","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/bjc.2017.422","article-title":"HER2 expression patterns in paired primary and metastatic endometrial cancer lesions","volume":"118","author":"Kylles\u00f8 Halle","year":"2018","journal-title":"Br J Cancer."},{"issue":"3","key":"2023100314251568100_CIT0069","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","article-title":"Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity","volume":"40","author":"Rottmann","year":"2021","journal-title":"Int J Gynecol Pathol."},{"issue":"1","key":"2023100314251568100_CIT0070","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N Engl J Med."}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/4\/341\/51838843\/aqad056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/160\/4\/341\/51838843\/aqad056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T13:17:10Z","timestamp":1696339030000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/160\/4\/341\/7189654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,2]]},"references-count":70,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,6,2]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqad056","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,6,2]]}}}